Day: September 22, 2022

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The presentation is scheduled to begin at 2:30 p.m. ET on Thursday, September 29, 2022. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product...

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1 study of iopofosine I 131 (iopofosine) in children and adolescents with inoperable relapsed or refractory high grade gliomas (HGGs). The grant was awarded by the National Institute of Health’s National Cancer Institute (NCI) based upon the initial signals of efficacy in the Phase 1 study, which is an international, open-label, dose escalation, safety study. The funding allows for an expansion from the Part 1a into the Part 1b portion of the company’s ongoing Phase 1 pediatric study. To accelerate...

HOUSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Itafos Inc. (TSXV: IFOS) (“Itafos” or the “Company”) announced today that it has entered into credit facilities (the “Credit Facilities”) with a syndicate of lenders led by RBC Capital Markets, as sole bookrunner and sole lead arranger, pursuant to which the lenders have advanced an US$85 million term loan (the “Term Loan”) to the Company and made available a US$35 million letter of credit facility (the “LC Facility”) and an US$80 million asset-based revolving credit facility (the “ABL Facility”). Together, the new Credit Facilities will provide Itafos with enhanced financial flexibility, a non-dilutive source of capital as well as the ability to refinance its existing debt. “The refinancing announced today represents the achievement of another important strategic milestone for the Company....

Results of a recent mining property survey commissioned by JSHG are likely the first time MENDM has approved a surface report conducted using drone-enabled LiDAR technologyJoshua Gold Resources Receives Approval of Drone LiDAR Mining Survey Results in Ontario, Canada Image of Joshua Gold Resources’ McCool property LiDAR survey showing an exposed rock outcropJoshua Gold Resources Receives Approval of Drone LiDAR Mining Survey Results in Ontario, Canada Map showing two indications of possible pegmatite outcrops revealed by the drone-enabled LiDAR surveyWOODSTOCK, ONTARIO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Joshua Gold Resources Inc. (OTC Pink: JSHG) is proud to announce that it has received what it believes is the very first government approval of mining survey results generated using drone-enabled LiDAR technology in the province...

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW), today announced the Company has entered an agreement with two major wholesale tool distributors in Switzerland, marking an expansion of European distribution that includes more than 250 retailers, nationwide.  This partnership represents a co-operative with Steinemann AG (“Steinemann”) and Tegro AG (“Tegro”). Steinemann, established in 1906, is the leading Swiss supplier of tools for the construction and garden-maintenance-related trades, distributing to over 250 retailers with a listing of ToughBuilt® products, soon reaching more than 110 SKUs. Tegro, a member of the international active-goods manufacturing MTS Group, distributes tools, electrical equipment, and automotive and outdoor adventure supplies...

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced its upcoming poster presentation related to its highly selective CDK9 inhibitor, GFH009, at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) being held on September 28 through October 1, 2022, in Houston, Texas and virtually. The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0. Additional presentation details can be found below: Title: “Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats” Abstract...

Company in Discussion with Potential Buyers Regarding Terms of a Long-Term Supply Contract to Monetize its Helium Gas Yield Including all of its Production Wells Drilled or to be Drilled Inside the Hugoton Gas Field in Haskell and Finney Counties, Kansas Covered by our Participation Agreement. Lenexa, KS, Sept. 22, 2022 (GLOBE NEWSWIRE) — American Noble Gas, Inc. (OTC-QB: IFNY) (“AMGAS” or the “Company”) announced initial results that confirm that it has become one of the few United States publicly traded companies that is actually producing and selling helium gas. The Company reported results that met its initial goals in terms of production forecasts and further confirmed that its initial production is generating positive cash-flow from its Hugoton Gas Field operations. The Company’s first production well, the Peyton 21-1,...

Chengdu, China, Sept. 22, 2022 (GLOBE NEWSWIRE) — Wetouch Technology Inc. (OTC: WETH) (“Wetouch” or “the Company”), a specialty manufacturer of medium to large sized projected capacitive touchscreens, today announced that it has completed approximately 80% of the construction work on its new high-standard production facility in Chengdu, for which the Company expects to complete the construction work before the end of 2022. The Company has completed roof sealing on the facility, which underscores Wetouch’s ongoing commitment to enhance its capacity and capability to meet fast-growing customer needs, including world’s top 500 enterprise customers such as Siemens, Canon and Delta. Wetouch will invest in total RMB76 million on the construction of the factory, and also invest another RMB20 million to build two...

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference:Date:     Wednesday, September 28, 2022Time:     1:45 PM ETFormat:     Panel Discussion & 1×1 meetingsPanel:     Trends and Challenges in Immuno-Oncology       Ladenburg Thalmann Healthcare Conference:Date:     Thursday, September 29, 2022Time:     10:30 AM ETWebcast:     Register HereMr. Oliviero will be presenting at the Ladenburg Thalmann Healthcare Conference. A webcast of the presentation will...

$300,000 Grant will Fund Additional Research for the Treatment of Hypoglycemia SAN CLEMENTE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $300,000 Small Business Innovation Research (SBIR) grant for the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device, which utilizes its proprietary vagus nerve block (vBloc) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes and metabolic disorders. Specifically, the grant will fund development of the device for the treatment of hypoglycemia. The technology is currently protected by 48 issued and pending patents related to vBloc, glucose control, AI and Bluetooth applications. The...